The level of premature death in the U.S. is still unacceptably high. But progress isn’t just about where you are; it’s also ...

Shares of Viking Therapeutics VKTX lost 18% yesterday after pharma giant Merck MRK announced its foray into the obesity space ...

Groundbreaking weight-loss drugs like Ozempic and Wegovy have understandably generated a lot of excitement, bringing hope to ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for ...

Today's health news includes the third human kidney transplant from a genetically modified pig, using stimulants to treat ...

Merck & Co. has secured a licensing agreement with Chinese drugmaker Hansoh Pharma for an experimental oral weight-loss drug, ...

Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

A previously unknown population of neurons in the hypothalamus may pave the way for new obesity treatments. Obesity impacts a ...